This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

J&J Prostate Cancer Drug Scores Big Win, Hurts Dendreon, Helps Medivation

Second update with new information on the Zytiga study plus other background.

RARITAN, N.J. ( TheStreet) -- Johnson & Johnson's (JNJ - Get Report) prostate cancer drug Zytiga prolonged the lives of patients with less advanced disease, according to results of a late-stage study announced Thursday.

Zytiga, a pill, is now in line to treat the same prostate cancer patients targeted by Dendreon (DNDN) with its Provenge immunotherapy. Dendreon shares fell 79 cents or 7% to $10.12 in Thursday trading on fears that Zytiga competition may further erode already-underperforming Provenge sales. Dendreon was down more sharply earlier Thursday but has rebounded because Zytiga's survival benefit in the study was not statistically significant.

Meantime, Medivation (MDVN - Get Report) shares jumped $11.81, or 18% to $76 because its prostate cancer drug MDV3100 is a close cousin to Zytiga. Medivation is also conducting a late-stage study of MDV3100 in the same population of prostate cancer patients.

J&J shares are up 1% to $64.98.

In the J&J study, patients with prostate cancer who had not yet received chemotherapy were treated with Zytiga plus the steroid prednisone or a placebo plus prednisone.

An independent data monitoring panel stopped the study early based on findings which showed the Zytiga therapy significantly delayed the growth of prostate cancer and helped patients live longer compared to placebo. All patients in the study will now be offered Zytiga treatment, according to J&J.

The Zytiga trial was designed with co-primary endpoints of progression-free survival (PFS) and overall survival. The PFS benefit was statistically significant in favor of Zytiga while the drug showed a "strong trend" in prolonging survival that did not meet statistical significance," said J&J spokeswoman Kellie McLaughlin.

The independent data monitors "stopped the trial based on the totality of the data they saw," said McLauglin, which included statistically significant benefit on all secondary endpoints.

J&J plans to submit the Zytiga trial for presentation at an upcoming medical meeting, which could be the American Society of Clinical Oncology (ASCO) annual meeting in June.

Zytiga was first approved in 2011 as a treatment for prostate cancer patients who have previously been treated with chemotherapy. Thursday's results open a much larger commercial opportunity for J&J because if approved, Zytiga will become a treatment option for men with less advanced prostate cancer.

J&J has not disclosed the extent to which Zytiga prolongs survival in pre-chemo prostate cancer patients, but if the convenient twice-daily pill works equally or better than Provenge, Dendreon could face further difficulties. Determining the real survival benefit of Zytiga could be confounded by the trial stopping early.

Provenge is a cancer vaccine custom made for each patient and requires three infusions over the course of one month. Reimbursement issues and wavering demand for Provenge have slowed Dendreon's launch efforts, so a new drug or two entering as a direct competitor won't help.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DNDN $0.06 -6.02%
JNJ $112.08 0.00%
MDVN $57.80 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs